[go: up one dir, main page]

WO2012068344A3 - Regulation of cathepsin l by its transcription factor dendrin - Google Patents

Regulation of cathepsin l by its transcription factor dendrin Download PDF

Info

Publication number
WO2012068344A3
WO2012068344A3 PCT/US2011/061142 US2011061142W WO2012068344A3 WO 2012068344 A3 WO2012068344 A3 WO 2012068344A3 US 2011061142 W US2011061142 W US 2011061142W WO 2012068344 A3 WO2012068344 A3 WO 2012068344A3
Authority
WO
WIPO (PCT)
Prior art keywords
cathepsin
dendrin
regulation
transcription factor
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/061142
Other languages
French (fr)
Other versions
WO2012068344A2 (en
Inventor
Jochen Reiser
Sanja Sever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of WO2012068344A2 publication Critical patent/WO2012068344A2/en
Anticipated expiration legal-status Critical
Publication of WO2012068344A3 publication Critical patent/WO2012068344A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions modulating the expression, function or activity of cathepsin L. (CatL.) are effective as protective against kidney disease or disorders and in the treatment of patients with kidney disease or disorders. The agents can target various pathways or molecules involved in CatL expression, activity or function.
PCT/US2011/061142 2010-11-17 2011-11-17 Regulation of cathepsin l by its transcription factor dendrin Ceased WO2012068344A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41478210P 2010-11-17 2010-11-17
US61/414,782 2010-11-17

Publications (2)

Publication Number Publication Date
WO2012068344A2 WO2012068344A2 (en) 2012-05-24
WO2012068344A3 true WO2012068344A3 (en) 2014-04-03

Family

ID=46084639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061142 Ceased WO2012068344A2 (en) 2010-11-17 2011-11-17 Regulation of cathepsin l by its transcription factor dendrin

Country Status (1)

Country Link
WO (1) WO2012068344A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107245502B (en) * 2017-06-14 2020-11-03 中国科学院武汉病毒研究所 CD2-binding protein (CD2AP) and its interacting proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272709A1 (en) * 2005-11-08 2010-10-28 The General Hospital Corporation Cathepsin l mediated diseases and associated methods and products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272709A1 (en) * 2005-11-08 2010-10-28 The General Hospital Corporation Cathepsin l mediated diseases and associated methods and products

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SUGITA ET AL.: "Acquisition of T regulatory function in cathepsin L-inhibited T cells by eye-derived CTLA-2alpha during inflammatory conditions.", J IMMUNOL, vol. 183, no. 8, 2009, pages 5013 - 22 *
SUGITA ET AL.: "Induction of T regulatory cells by cytotoxic T-lymphocyte antigen-2a on corneal endothelial cells.", INVEST OPHTHALMOL VIS SCI., vol. 52, no. 5, 20 April 2011 (2011-04-20), pages 2598 - 2605 *
SUGITA ET AL.: "Retinal pigment epithelium-derived CTLA-2alpha induces TGFbeta-producing T regulatory cells.", J IMMUNOL., vol. 181, no. 11, 2008, pages 7525 - 7536 *
ZHOU ET AL.: "Ocular immune privilege.", F1000 BIOLOGY REPORTS, vol. 2, no. 3, January 2010 (2010-01-01), pages 2, COL 2 *

Also Published As

Publication number Publication date
WO2012068344A2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2012062925A3 (en) Compounds and methods for treating pain
WO2009089494A3 (en) Pharmaceutical compositions
WO2012020307A3 (en) Therapeutic uses of microvesicles and related micrornas
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
EA202091999A3 (en) APPLICATION OF DPP IV INHIBITORS
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA201200793A1 (en) TREATMENT OF GENOTYPED PATIENTS WITH DIABETES DPP-4 INHIBITORS, SUCH AS LINAGLIPTIN
HK1197276A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
HK1198869A1 (en) Combination treatments for hepatitis c
WO2011146674A3 (en) Treatment of bcl2-like 11 (bcl2l11) related diseases by inhibition of natural antisense transcript to bcl2l11
WO2011082409A3 (en) Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2012097264A3 (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
UA107687C2 (en) A combined composition comprising as active ingredients l-carnitine or propionyl l-carnitine, troxerutine, diosmlne and hesperidine, for the prevention and/or treatment of chronic venous diseases
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
WO2013059233A3 (en) Thermoresponsive compositions for dermatological use and methods thereof
WO2011097522A3 (en) Combination methods for treatment of disease
NZ602145A (en) Ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders
WO2013138338A3 (en) Methods for treating tissue damage associated with ischemia with apoliporotein d
WO2008011473A3 (en) Compositions and their uses directed to hbxip
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
WO2012068344A3 (en) Regulation of cathepsin l by its transcription factor dendrin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11841165

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11841165

Country of ref document: EP

Kind code of ref document: A2